Grup 2b ve 2be β-Laktamazlar

Gülçin Bayramoğlu

doi:10.37609/akya.4089

Yazarlar

Gülçin Bayramoğlu

https://orcid.org/0000-0002-6103-3127

DOI: https://doi.org/10.37609/akya.4089.c5930

Özet

Bush-Jacoby sınıflandırmasında 2b ve 2be altında toplanan serin β-laktamazlar, Ambler sınıflandırmasında sınıf A içinde yer almaktadır. Grup 2b’de, penisilinler, birinci ve ikinci kuşak sefalosporinleri hidrolize eden, TEM-1, TEM-2 ve SHV-1 gibi β-laktamazlar yer alırken; CTX-M, TEM ve SHV türevleri gibi genişlemiş spektrumlu β-laktamaz (GSBL) varyantlarının çoğu, grup 2be’de yer almaktadır. Bu derlemede, 2b ve 2be grubu enzimlerin başlıca özellikleri, sınıflandırılması, substrat ve inhibitör spektrumları güncel literatür ışığında irdelenmiştir.

Serine β-lactamases classified under groups 2b and 2be in the Bush-Jacoby classification are included in class A according to the Ambler classification. Group 2b includes β-lactamases such as TEM-1, TEM-2, and SHV-1, which hydrolyze penicillins and first- and second-generation cephalosporins, whereas most extended-spectrum β-lactamase (ESBL) variants, including derivatives of CTX-M, TEM, and SHV, are placed in group 2be. In this review, the main characteristics, classification, substrate and inhibitor profiles of enzymes in groups 2b and 2be are reviewed in the light of the current literature.

Referanslar

Bush K, Bradford PA. Interplay between β-lactamases and new β-lactamase inhibitors. Nat Rev Microbiol. 2019;17(5):295-306. https://doi.org/10.1038/s41579-019-0159-8.

Nagshetty K, Shilpa BM, Patil SA, Shivannavar CT, Manjula NG. An overview of extended spectrum beta lactamases and metallo beta lactamases. Adv Microbiol. 2021;11(01):37-62. https://doi.org/10.4236/aim.2021.111004.

Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657-86. https://doi.org/10.1128/CMR.18.4.657-686.2005.

Castanheira M, Simner PJ, Bradford PA. Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection. JAC Antimicrob Resist. 2021;3(3):dlab092. https://doi.org/10.1093/jacamr/dlab092.

Liakopoulos A, Mevius D, Ceccarelli D. A Review of SHV Extended-Spectrum β-Lactamases: Neglected Yet Ubiquitous. Front Microbiol. 2016;7:1374. https://doi.org/10.3389/fmicb.2016.01374.

Zhang S, Liao X, Ding T, Ahn J. Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria. Antibiotics (Basel). 2024;13(3):260. https://doi.org/10.3390/antibiotics13030260.

Beta-Lactamase DataBase. [http://bldb.eu/Enzymes.php] (Erişim tarihi: 22 Mart 2025).

Naas T, Oueslati S, Bonnin RA, Dabos LM, Zavala A, Dortet L, et al. Beta-Lactamase DataBase (BLDB) – Structure and Function. J. Enzyme Inhib. Med. Chem. 2017; 32:917-919. https://doi.org/10.1080/14756366.2017.1344235.

Philippon A, Slama P, Dény P, Labia R. A Structure-Based Classification of Class A β-Lactamases, a Broadly Diverse Family of Enzymes. Clin Microbiol Rev. 2016;29(1):29-57. https://doi.org/10.1128/CMR.00019-15.

Singh A, Shahid M, Sami H, Shadab M, Khan HM. Class A Type Β-Lactamases. In: Shahid M, Singh A, Sami H (Eds.) Beta-Lactam Resistance in Gram-Negative Bacteria: Threats and Challenges. Springer Nature Singapore, 2022: 35–80. https://doi.org/10.1007/978-981-16-9097-6_4.

Naas T, Poirel L, Nordmann P. Minor extended-spectrum beta-lactamases. Clin Microbiol Infect. 2008;14 Suppl 1:42-52. https://doi.org/10.1111/j.1469-0691.2007.01861.x Erratum in: Clin Microbiol Infect. 2008;14 Suppl 5:21-4.

Bush K. Bench-to-bedside review: The role of beta-lactamases in antibiotic-resistant Gram-negative infections. Crit Care. 2010;14(3):224. https://doi.org/10.1186/cc8892.

Rossolini GM, Arena F, Giani T. Mechanisms of Antibacterial Resistance. In: Cohen J, Powderly WG, Opal SM (Eds.) Infectious Diseases, 4th ed., Elsevier Ltd, 2017:1181-1196.e1. https://doi.org/10.1016/B978-0-7020-6285-8.00274-4.

Van Bambeke F, Mingeot-Leclercq M-P, Glupczynski Y, Tulkens PM. Mechanisms of Action. In: Cohen J, Powderly WG, Opal SM (Eds.) Infectious Diseases, 4th ed., Elsevier Ltd, 2017:1162–1180. https://doi.org/10.1016/B978-0-7020-6285-8.00274-4.

Husna A, Rahman MM, Badruzzaman ATM, et al. Extended-Spectrum β-Lactamases (ESBL): Challenges and Opportunities. Biomedicines. 2023;11(11):2937. https://doi.org/10.3390/biomedicines11112937.

Opal SM, Pop-Vicas A. Molecular mechanisms of antibiotic resistance in bacteria. In: Bennett JE, Dolin R, Blaser MJ (Eds.) Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. 9th ed. Philadelphia, PA: Elsevier, Inc; 2020: 222-239.e3.

Tamma PD, Heil EL, Justo JA, Mathers AJ, Satlin MJ, Bonomo RA. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024:ciae403. https://doi.org/10.1093/cid/ciae403.

Ur Rahman S, Ali T, Ali I, Khan NA, Han B, Gao J. The Growing Genetic and Functional Diversity of Extended Spectrum Beta-Lactamases. Biomed Res Int. 2018;2018:9519718. https://doi.org/10.1155/2018/9519718.

Ghafourian S, Sadeghifard N, Soheili S, Sekawi Z. Extended Spectrum Beta-lactamases: Definition, Classification and Epidemiology. Curr Issues Mol Biol. 2015;17:11-21.

Kazmierczak KM, de Jonge BLM, Stone GG, Sahm DF. Longitudinal analysis of ESBL and carbapenemase carriage among Enterobacterales and Pseudomonas aeruginosa isolates collected in Europe as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance programme, 2013-17. J Antimicrob Chemother. 2020;75(5):1165-1173. https://doi.org/10.1093/jac/dkz571.

Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother. 2004;48(1):1-14. https://doi.org/10.1128/AAC.48.1.1-14.2004.

Shurina BA, Page RC. Structural Comparisons of Cefotaximase (CTX-M-ase) Sub Family Front Microbiol. 2021;12:688509. https://doi.org/10.3389/fmicb.2021.688509.

D'Andrea MM, Arena F, Pallecchi L, Rossolini GM. CTX-M-type β-lactamases: a successful story of antibiotic resistance. Int J Med Microbiol. 2013;303(6-7):305-17. https://doi.org/10.1016/j.ijmm.2013.02.008.

Ortiz de la Rosa JM, Nordmann P, Poirel L. ESBLs and resistance to ceftazidime/avibactam and ceftolozane/tazobactam combinations in Escherichia coli and Pseudomonas aeruginosa. J Antimicrob Chemother. 2019;74(7):1934-1939. https://doi.org/10.1093/jac/dkz149.

Yousefi B, Kashanipoor S, Mazaheri P, et al. Cefiderocol in Combating Carbapenem-Resistant Acinetobacter baumannii: Action and Resistance. Biomedicines. 2024;12(11):2532. https://doi.org/10.3390/biomedicines12112532.